RESULTS FROM APOLLO PHASE III STUDY OF PATISIRAN, THE FIRST APPROVED RNAI THERAPEUTIC, IN HEREDITARY ATTR AMYLOIDOSIS PATIENTS WITH POLYNEUROPATHY.

被引：0
|
作者：
Zhang, X. [1 ]
Sweetser, M. T. [1 ]
Robbie, G. J. [1 ]
机构：
[1] Alnylam Pharmaceut Inc, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
E-009
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [41] Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: post-hoc analysis of the APOLLO-B study
    Damy, T.
    Shah, Z.
    Drachman, B.
    Schwartzmann, P.
    Tinoco Mesquita, C.
    Polydefkis, M.
    Obici, L.
    Jay, P.
    Bender, S.
    Capocelli, K.
    Hanna, M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [42] PATISIRAN STABILIZES CARDIAC MECHANICS IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS: POST-HOC ANALYSIS OF THE APOLLO STUDY
    Rosenblum, Hannah
    Griffin, Jan
    Minamisawa, Masatoshi
    Prasad, Narayana
    Vest, John
    White, Matthew
    Solomon, Scott
    Burkhoff, Daniel
    Maurer, Mathew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 524 - 524
  • [43] Phase 2 Open-Label Extension Study (OLE) of Patisiran, an Investigational RNAi Therapeutic for Familial Amyloid Polyneuropathy (FAP)
    Adams, David
    Coelho, Teresa
    Conceicao, Isabel
    Waddington-Cruz, Marcia
    Schmidt, Hartmut
    Buades, Juan
    Campistol, Josep
    Pouget, Jean
    Berk, John
    Falzone, Rick
    White, Lindsey
    Bettencourt, Brian
    Cehelsky, Jeff
    Nochur, Sara
    Vaishnaw, Akshay
    Gollob, Jared
    Suhr, Ole B.
    ANNALS OF NEUROLOGY, 2015, 78 : S113 - S114
  • [44] Phase 2 Open-Label Extension Study (OLE) of Patisiran, an Investigational RNAi Therapeutic for Familial Amyloid Polyneuropathy (FAP)
    Adams, David
    Coelho, Teresa
    Conceicao, Isabel
    Waddington-Cruz, Marcia
    Schmidt, Hartmut
    Buades, Juan
    Campistol, Josep
    Pouget, Jean
    Berk, John
    Falzone, Rick
    White, Lindsey
    Bettencourt, Brian
    Cehelsky, Jeff
    Nochur, Sara
    Vaishnaw, Akshay
    Gruis, Kirsten
    Gollob, Jared
    Suhr, Ole
    NEUROLOGY, 2016, 86
  • [45] Response by Solomon to Letter Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study"
    Solomon, Scott D.
    CIRCULATION, 2019, 140 (02) : E92 - E93
  • [46] Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
    Zhang, Xiaoping
    Goel, Varun
    Attarwala, Husain
    Sweetser, Marianne T.
    Clausen, Valerie A.
    Robbie, Gabriel J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (01): : 37 - 49
  • [47] APOLLO-B, a Study of Patisiran in Patients With Transthyretin Cardiac Amyloidosis: Primary LongTerm Results From the Open-Label Extension Period
    Hung, Rebecca R.
    Correia, Edileide D.
    Berk, John L.
    Drachman, Brian
    Fontana, Marianna
    Gillmore, Julian D.
    Mesquita, Claudio T.
    Simoes, Marcus V.
    Yureneva, Elena
    White, Matthew T.
    Sweetser, Marianne T.
    Jay, Patrick Y.
    Vest, John
    Maurer, Mathew S.
    CIRCULATION, 2023, 148
  • [48] Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study
    Rosenblum, Hannah R.
    Griffin, Jan M.
    Minamisawa, Masatoshi
    Prasad, Narayana
    Vest, John
    White, Matthew T.
    Solomon, Scott D.
    Burkhoff, Daniel
    Maurer, Mathew S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (05) : 727 - 736
  • [49] NEUROFILAMENT LIGHT CHAIN IN ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY: ANALYSIS FROM THE PHASE 3 APOLLO-B STUDY
    Gonzalez-Duarte, Alejandra
    Fontana, Marianna
    Sekijima, Yoshiki
    Obici, Laura
    Bender, Shaun
    Ticau, Simina
    Aldinc, Emre
    Gillmore, Julian
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S142 - S143
  • [50] LONG-TERM USE OF PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS: 12 MONTH EFFICACY AND SAFETY FROM GLOBAL OPEN LABEL EXTENSION STUDY
    Gonzalez-Duarte, Alejandra
    Coelho, Teresa
    Adams, David
    Yang, Chih-Chao
    Polydefkis, Michael
    Kristen, Arnt
    Tournev, Ivaylo
    Schmidt, Hartmut
    Berk, John
    Lin, Kon-Ping
    Gandhi, Pritesh
    Sweetser, Marianne
    White, Matthew
    Gollob, Jared
    Suhr, Ole
    MUSCLE & NERVE, 2018, 58 : S51 - S51
12345